KEVIN HANAWAY: Open Payments
NPI 1447666086 · LIGHTHOUSE POINT, FL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$989 in 40 payments from 15 companies in 2025. Trend: 2023 $207 · 2024 $1,251 · 2025 $989
Food & beverage: $989
| Company | Payments | Amount |
|---|---|---|
| GlaxoSmithKline, LLC. | 7 | $156 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 4 | $119 |
| AstraZeneca Pharmaceuticals LP | 5 | $94 |
| Verona Pharma, Inc. | 4 | $92 |
| Novartis Pharmaceuticals Corporation | 3 | $88 |
| Viatris Specialty LLC | 3 | $87 |
| Actelion Pharmaceuticals US, Inc. | 2 | $76 |
| GENZYME CORPORATION | 2 | $59 |
| Insmed, Inc. | 2 | $45 |
| United Therapeutics Corporation | 2 | $42 |
Products named: OFEV, NUCALA, DUPIXENT, FASENRA, Ohtuvayre, XOLAIR, YUPELRI, UPTRAVI.
Industry payments across FL — which companies pay providers there.
